Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) on Friday announced the launch of AstraZeneca Direct, an online platform designed to provide eligible US patients with a simple, convenient way to access prescribed medications at a transparent cash price with home delivery.
The service targets patients with chronic conditions, including asthma, diabetes, heart failure, and chronic kidney disease, as well as those seeking flu protection.
From October, patients with prescriptions for AIRSUPRA (albuterol/budesonide) or FARXIGA (dapagliflozin) can purchase these medications directly through the platform for up to 70% off the list price. FLUMIST (Influenza Vaccine Live, Intranasal) will also be available for home delivery.
Joris Silon, US country president at AstraZeneca, said that the platform complements AstraZeneca's existing patient support programmes and provides transparent pricing and convenient access.
The platform will be accessible at AstraZenecaDirect.com starting 1 October 2025.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses